# US 2021/0189427 A1 · Compositions and methods for gene delivery to the airways and/or lungs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0189427 A1
- Document ID: US20210189427A1
- Status: Published application
- Kind: A1
- Application number: 17/127,416
- Filed: 2020-12-18
- Published: 2021-06-24
- Earliest claimed: 2019-12-20
- Assignees: Krystal Biotech, Inc.
- Applicants: Krystal Biotech, Inc.
- Inventors: Suma KRISHNAN; Trevor Parry; Pooja Agarwal; Sara Artusi; Mladen Yovchev
- Web page: https://patentgrep.com/patent/US20210189427A1

## CPC

- C12N 15/86: Viral vectors
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 38/1709: {from mammals}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 14/8125: {Alpha-1-antitrypsin}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A01K 2227/105: Murine
- A01K 2227/106: Primate
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61M 11/005: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- C12N 2710/00043: viral genome or elements thereof as genetic vector
- C12N 2710/00071: Demonstrated in vivo effect
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide (e.g., an inhaled therapeutic polypeptide, such as a human alpha-1-antitrypsin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for delivering the polypeptide to one or more cells of the respiratory tract and/or for the treatment of a disease affecting the lungs, such as alpha-1-antitrypsin deficiency); and articles of manufacture or kits thereof.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A pharmaceutical composition comprising:
(a) a herpes virus comprising a recombinant herpes virus genome, wherein the recombinant herpes virus genome comprises one or more polynucleotides encoding an inhaled therapeutic polypeptide; and
(b) a pharmaceutically acceptable excipient.

### Claim at position 3

-62. (canceled)

### Claim 63 (depends on 45)

A method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of a disease affecting the airways and/or lungs in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 45.

### Claim at position 5

-81. (canceled)

### Claim 82 (depends on 63)

The method of claim 63, wherein the subject is a human.

### Claim 83 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered orally, intranasally, intratracheally, or via inhalation to the subject.

### Claim 84

(canceled)

### Claim 85

(canceled)

### Claim 86 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered using a dry powder inhaler, a pressurized metered dose inhaler, a soft mist inhaler, a nebulizer, or an electrohydrodynamic aerosol device.

### Claim 87 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is administered using a nebulizer.

### Claim 88

(canceled)

### Claim 89

A method of delivering a polypeptide to one or more cells of the respiratory tract of a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
a) a herpes virus comprising a recombinant herpes virus genome, wherein the recombinant herpes virus genome comprises one or more polynucleotides encoding the polypeptide; and
b) a pharmaceutically acceptable carrier.

### Claim 90 (depends on 89)

The method of claim 89, wherein the subject suffers from a disease affecting the airways and/or lungs.

### Claim 91 (depends on 90)

The method of claim 90, wherein the disease is selected from the group consisting of alpha-1-antitrypsin deficiency, pulmonary alveolar microlithiasis, primary ciliary dyskinesia, congenital pulmonary alveolar proteinosis, pulmonary arterial hypertension, and pulmonary fibrosis.

### Claim at position 16

-110. (canceled)

### Claim 111 (depends on 89)

The method of claim 89, wherein the pharmaceutical composition is administered using a dry powder inhaler, a pressurized metered dose inhaler, a soft mist inhaler, a nebulizer, or an electrohydrodynamic aerosol device.

### Claim 112 (depends on 89)

The method of claim 89, wherein the pharmaceutical composition is administered using a nebulizer.

### Claim 113 (depends on 112)

The method of claim 112, wherein the nebulizer is a vibrating mesh nebulizer.

### Claim 114 (depends on 45)

The pharmaceutical composition of claim 45, wherein the recombinant herpes virus genome is selected from the group consisting of a recombinant herpes simplex virus genome, a recombinant varicella zoster virus genome, a recombinant human cytomegalovirus genome, a recombinant herpesvirus 6A genome, a recombinant herpesvirus 6B genome, a recombinant herpesvirus 7 genome, a recombinant Epstein-Barr virus genome, a recombinant Kaposi's sarcoma-associated herpesvirus genome, and any derivatives thereof.

### Claim 115 (depends on 45)

The pharmaceutical composition of claim 45, wherein the recombinant herpes virus genome is a recombinant herpes simplex virus genome.

### Claim 116 (depends on 115)

The pharmaceutical composition of claim 115, wherein the recombinant herpes simplex virus genome is a recombinant herpes simplex virus type 1 (HSV-1) genome, a recombinant herpes simplex virus type 2 (HSV-2) genome, or any derivatives thereof.

### Claim 117 (depends on 115)

The pharmaceutical composition of claim 115, wherein the recombinant herpes simplex virus genome is a recombinant herpes simplex virus type 1 (HSV-1) genome.

### Claim 118 (depends on 45)

The pharmaceutical composition of claim 45, wherein the inhaled therapeutic polypeptide is selected from the group consisting of an Alpha-1-antitrypsin polypeptide, a Sodium-dependent phosphate transport protein 2B polypeptide, a Dynein heavy chain 5 axonemal polypeptide, a Dynein heavy chain 11 axonemal polypeptide, a Coiled-coil domain-containing protein 39 polypeptide, a Dynein intermediate chain 1 axonemal polypeptide, a Coiled-coil domain-containing protein 40 polypeptide, a Coiled-coil domain containing protein 103 polypeptide, a Sperm-associated antigen 1 polypeptide, a Zinc finger MYND domain-containing protein 10 polypeptide, an Armadillo repeat containing protein 4 polypeptide, a Coiled-coil domain-containing protein 151 polypeptide, a Dynein intermediate chain 2 axonemal polypeptide, a Radial spoke head 1 homolog polypeptide, a Coiled-coil domain-containing protein 114 polypeptide, a Radial spoke head protein 4 homolog A polypeptide, a Dynein assembly factor 1 axonemal polypeptide, a Dynein assembly factor 2 axonemal polypeptide, a Leucine-rich repeat-containing protein 6 polypeptide, a Pulmonary surfactant-associated protein B polypeptide, a Pulmonary surfactant-associated protein C polypeptide, a Homeobox protein Nkx-2.1 polypeptide, an ATP-binding cassette sub-family A member 3 polypeptide, a Cytokine receptor common subunit beta polypeptide, a Granulocyte-macrophage colony-stimulating factor receptor subunit alpha polypeptide, a Bone morphogenetic protein receptor type-2 polypeptide, a Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 polypeptide, a serine/threonine-protein kinase receptor R3 polypeptide, an Endoglin polypeptide, a Mothers against decapentaplegic homolog 9 polypeptide, a Caveolin-1 polypeptide, a Potassium channel subfamily K member 3 polypeptide, an eIF-2-alpha kinase GCN2 polypeptide, a Pulmonary surfactant-associated protein A2 polypeptide, a Telomerase reverse transcriptase polypeptide, a Dyskerin polypeptide, a Regulator of telomere elongation helicase 1 polypeptide, a Poly(A)-specific ribonuclease PARN polypeptide, a TERF1-interacting nuclear factor 2 polypeptide, an H/ACA ribonucleoprotein complex non-core subunit NAF1 polypeptide, a Mucin-5B polypeptide, a Desmoplakin polypeptide, a CST complex subunit STN1 polypeptide, and a Dipeptidyl peptidase 9 polypeptide.

### Claim 119 (depends on 45)

The pharmaceutical composition of claim 45, wherein the inhaled therapeutic polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 3-46.

### Claim 120 (depends on 45)

The pharmaceutical composition of claim 45, wherein the inhaled therapeutic polypeptide is an alpha-1-antitrypsin polypeptide.

### Claim 121 (depends on 45)

The pharmaceutical composition of claim 45, wherein the inhaled therapeutic polypeptide is a Dynein heavy chain 5 axonemal polypeptide.
